Two separate hematology and oncology signals highlight rapid momentum in late-stage and early clinical development. First, a report on a leukemia program describes how recent phase 3 data for the CLL sequence sits at a decision point for clinicians, with experts urging careful treatment ordering despite strong outcomes. Separately, a phase 1 cellular therapy trial combining NK and T cells (SDH-Combi) generated early promise in hard-to-treat solid tumors after surgery, chemotherapy and radiation. Together, the updates underscore both the sequencing debates in indolent blood cancers and the continued push toward multi-modality cell therapies for refractory solid tumors.